Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00821951 · ClinicalTrials.gov registry record · Phase 1

Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer

A Phase 1 study of Non-small Cell Lung Cancer (NSCLC), sponsored by Yale University.

Completed
Registry status
Phase 1
Development phase
17
Enrollment target
1
Study location

NCT00821951 is a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) that has completed, run by Yale University. The registered enrollment target is 17 participants, below the 288-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00821951, a Phase 1 study of Non-small Cell Lung Cancer (NSCLC), has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 1
Development phase
17 participants
Enrollment target
1
Study location

Study Summary

This is a dose escalation study that will assess the safety of Vorinostat, a Histone Deacetylase (HDAC) inhibitor, in combination with palliative radiotherapy in patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC). Vorinostat has been approved for use in patients with cutaneous T-cell lymphomas, but several pre-clinical studies suggest activity in lung cancer cell lines. Several HDAC inhibitors,including Vorinostat, may enhance the effect of radiotherapy, and this study will seek to confirm this.

Conditions Studied

Non-small Cell Lung Cancer (NSCLC)

Interventions

  • RADIATION Radiotherapy
  • DRUG Vorinostat

Study Locations (1)

Connecticut

  • Yale University School of Medicine - New Haven

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2009-05
Est. Completion 2012-07
Phase Phase 1

Sponsor

Yale University

1,492 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00821951

The ClinicalTrials.gov registry entry for NCT00821951 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 288-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (94% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 2 interventions - of which Radiotherapy is the first listed.

NCT00821951 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT00821951 about?

NCT00821951 is a clinical study titled "Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer". This is a dose escalation study that will assess the safety of Vorinostat, a Histone Deacetylase (HDAC) inhibitor, in combination with palliative radiotherapy in patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC). Vorinostat has been approved for use in patients with cutaneous T...

What is the current status of trial NCT00821951?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2009-05. Estimated completion is 2012-07.

What conditions does trial NCT00821951 study?

This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC).

What interventions are being tested in trial NCT00821951?

The interventions under investigation include: Radiotherapy (RADIATION), Vorinostat (DRUG).

Who is sponsoring clinical trial NCT00821951?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00821951 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-small Cell Lung Cancer (NSCLC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-small Cell Lung Cancer (NSCLC)

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.